To be clear, it's not impossible, and OWS surely has assumptions to support this. And yes we must be ambitious.
But many will assume and/or communicate that these *targets* are what they can *expect* to happen, when there are many unknowns and execution risks. 1/
A few big ones: (1) we don't have *any* efficacy data, incl in elderly; (2) manufacturing scale-up is complex and delays very common; (3) first-time cold-chain, distribution and logistics; and (4) presumably more than one vaccine needs to succeed for this to happen; etc. 2/
As we've learned repeatedly, we need to get better at communicating risk and unknowns. And we need to be clear about what we *hope* will happen vs. what is *likely* to happen, taking those risks and unknowns into account. Leaders' credibility and public trust depend on it. 3/
Similar view from @ScottGottliebMD in conversation with @margbrennan, calling the timeline "aggressive" and explaining why.
I'll maintain "extraordinarily optimistic" and reiterate the need to separate "best case" from "base case."
Yes the first COVID vaccines will face challenges, but the overall situation is quite promising. Thread.
First, we can’t predict how good the first vaccines will be - we need Phase 3 data. We shouldn’t assume they will be very effective, poorly-effective, or “so-so.” 1/
It's true that some "second wave" vaccines will be better, because they're intended to address gaps, but that doesn't mean the first vaccines won't be good.
Second, don't underestimate complexity of aligning multiple Phase 3 vaccine programs around a single master protocol. 2/
This would have delayed the Phase 3 trials, with a human cost. It's not just about companies aligning with each other and regulators - it requires rigorous matching of the placebo arm with multiple vaccine arms to avoid reaching the wrong conclusions about efficacy. 3/
This is a thread on the use of antibody tests (serology) to gauge individual risk for COVID-19 infection. It's triggered by the recent @WHO guidance and the push for "immunity certificates" to get people back into the workplace. @jeremyfarrar@laurie_garrett@mvankerkhove 1/8
The science isn’t there, and it could get us into trouble for two reasons: partial immunity and risk perception. A history of COVID-19 and/or circulating antibodies may not translate to complete protection in all individuals. This is the case for circulating coronaviruses. 2/8
We’ll likely see spectrum of protection, with many people having "partial immunity," meaning that they can be reinfected but with less severe symptoms or no symptoms at all. These individuals may "shed" lower amounts of virus but could still infect others. 3/8